Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02059967

Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC

A Phase I Image-Guided Adaptive Radiotherapy Study Using Active Breathing Control (ABC) and Simultaneous Integrated Boost for Patients With Inoperable Non-Small Cell Lung Cancer

Status
Withdrawn
Phase
Phase 1
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Virginia Commonwealth University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase I trial studies the side effects and best dose of image-guided adaptive radiation therapy using active breathing control when given together with chemotherapy and simultaneous integrated boost in treating patients with stage IIA-IIIB non-small cell lung cancer that cannot be removed by surgery. Image-guided adaptive radiation therapy aims radiation therapy right at the tumor so that higher radiation doses can be given without causing bad side effects. Giving these higher doses may help control the tumor better. Breathing causes organs and tissues, including the tumor, to move within the chest. Active breathing control may reduce the volume that needs to be treated. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving image-guided adaptive radiation therapy using active breathing control with chemotherapy and simultaneous integrated boost may be an effective treatment for non-small cell lung cancer.

Detailed description

OUTLINE: This is a dose-escalation study of IGART. Patients undergo IGART using active breathing control (ABC) 5 days a week for 7 weeks, for a total of 33 fractions with simultaneous integrated volume adapted boost (SIVAB) during fractions 26-33. Patients also receive paclitaxel intravenously (IV) over 1 hour and carboplatin IV over 30 minutes once a week for 6 weeks. After completion of study treatment, patients are followed up periodically for 5 years.

Conditions

Interventions

TypeNameDescription
DRUGPaclitaxelGiven IV
RADIATIONimage-guided adaptive radiation therapyUndergo IGART
DRUGcarboplatinGiven IV

Timeline

Start date
2014-03-01
Primary completion
2015-01-01
Completion
2015-01-01
First posted
2014-02-11
Last updated
2015-03-19

Source: ClinicalTrials.gov record NCT02059967. Inclusion in this directory is not an endorsement.